The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.

[1]  Nikos Evangelou,et al.  A Comparison of 3T and 7T in the Detection of Small Parenchymal Veins Within MS Lesions , 2009, Investigative radiology.

[2]  Jeffrey A. Cohen,et al.  Differential diagnosis of suspected multiple sclerosis: a consensus approach , 2008, Multiple sclerosis.

[3]  Jie Luo,et al.  In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique , 2010, NeuroImage.

[4]  B. Caffo,et al.  Axial 3D gradient-echo imaging for improved multiple sclerosis lesion detection in the cervical spinal cord at 3T , 2013, Neuroradiology.

[5]  R. Hintzen,et al.  Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes , 2013, European journal of neurology.

[6]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[7]  Hannes Deutschmann,et al.  The “central vein sign”: is there a place for susceptibility weighted imaging in possible multiple sclerosis? , 2013, European Radiology.

[8]  S. Pierre,et al.  A Historical Perspective on Gender. , 1999 .

[9]  M. Ramanathan,et al.  Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis , 2009, Neurology.

[10]  Bejoy Thomas,et al.  Principles, techniques, and applications of T2*-based MR imaging and its special applications. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[11]  Peter Gordon Morris,et al.  Optimisation of T₂*-weighted MRI for the detection of small veins in multiple sclerosis at 3 T and 7 T. , 2013, European journal of radiology.

[12]  J. Dawson,et al.  XVIII.–The Histology of Disseminated Sclerosis , 1916, Transactions of the Royal Society of Edinburgh.

[13]  F Barkhof,et al.  MR venography of multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[14]  M. Freedman.  Long-term follow-up of clinical trials of multiple sclerosis therapies , 2011, Neurology.

[15]  E. Ringelstein,et al.  Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis , 2012, Multiple sclerosis.

[16]  Natalia Petridou,et al.  Fast high resolution whole brain T2* weighted imaging using echo planar imaging at 7T , 2011, NeuroImage.

[17]  O. Ciccarelli,et al.  Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  M. Ramanathan,et al.  Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  E. Haacke,et al.  High‐resolution BOLD venographic imaging: a window into brain function , 2001, NMR in biomedicine.

[20]  B. Bolster,et al.  Characterization of Multiple Sclerosis Plaques Using Susceptibility-Weighted Imaging at 1.5 T: Can Perivenular Localization Improve Specificity of Imaging Criteria? , 2015, Journal of computer assisted tomography.

[21]  D. Reich,et al.  Rapid, high-resolution, whole-brain, susceptibility-based MRI of multiple sclerosis , 2014, Multiple sclerosis.

[22]  P S Morgan,et al.  Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions , 2011, Neurology.

[23]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[24]  Siegfried Trattnig,et al.  Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI , 2011, Journal of magnetic resonance imaging : JMRI.

[25]  Marco Rovaris,et al.  MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study , 2007, The Lancet Neurology.

[26]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[27]  M. Díaz-Sánchez,et al.  Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes , 2012, Multiple sclerosis.

[28]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[29]  L. V. Bogaert.  POST‐INFECTIOUS ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS: THE SIGNIFICANCE OF PERIVENOUS ENCEPHANLOMYELITIS , 1950 .

[30]  J R Reichenbach,et al.  Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. , 1997, Radiology.

[31]  Pascal Sati,et al.  FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. , 2012, Radiology.

[32]  Nikos Evangelou,et al.  Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. , 2013, JAMA neurology.

[33]  F. Barkhof,et al.  MRI mimics of multiple sclerosis. , 2014, Handbook of clinical neurology.

[34]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[35]  Christian Denk,et al.  Susceptibility weighted imaging with multiple echoes , 2010, Journal of magnetic resonance imaging : JMRI.

[36]  Ravi S. Menon,et al.  Venocentric Lesions: An MRI Marker of MS? , 2013, Front. Neurol..

[37]  Gregory F. Wu,et al.  The contemporary spectrum of multiple sclerosis misdiagnosis , 2016, Neurology.

[38]  Mike P. Wattjes,et al.  Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla , 2014, European Radiology.

[39]  S. Xiong,et al.  [A multicentre retrospective study of pulmonary mycosis clinically proven from 1998 to 2007]. , 2011, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[40]  H. Brückmann,et al.  Presence of a central vein within white matter lesions on susceptibility weighted imaging: a specific finding for multiple sclerosis? , 2011, Neuroradiology.

[41]  J. Dawson,et al.  The Histology of Disseminated Sclerosis , 1916, Edinburgh Medical Journal.

[42]  P. Morgan,et al.  Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions , 2016, Multiple sclerosis.

[43]  Yu-Chung N. Cheng,et al.  Susceptibility weighted imaging (SWI) , 2004, Zeitschrift fur medizinische Physik.

[44]  L. Mazzoni,et al.  SWI enhances vein detection using gadolinium in multiple sclerosis , 2015, Acta radiologica open.

[45]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[46]  Jullie W Pan,et al.  DEMONSTRATING THE PERIVASCULAR DISTRIBUTION OF MS LESIONS IN VIVO WITH 7-TESLA MRI , 2008, Neurology.

[47]  C. W. Adams,et al.  The onset and progression of the lesion in multiple sclerosis , 1975, Journal of the Neurological Sciences.

[48]  Y. Ge,et al.  Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica , 2013, Multiple sclerosis international.

[49]  B. Scheithauer,et al.  Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. , 2010, Brain : a journal of neurology.

[50]  F. Paul,et al.  Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study , 2014, Multiple sclerosis.

[51]  D. Reich,et al.  Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis , 2016, Multiple sclerosis.

[52]  Mike P. Wattjes,et al.  Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics , 2014, Journal of Neurology.

[53]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process , 2015, Nature Reviews Neurology.

[54]  Siegfried Trattnig,et al.  Veins in plaques of multiple sclerosis patients – a longitudinal magnetic resonance imaging study at 7 Tesla – , 2015, European Radiology.

[55]  Dennis Bourdette,et al.  “Undiagnosing” multiple sclerosis , 2012, Neurology.

[56]  D. Reich,et al.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis , 2016, American Journal of Neuroradiology.

[57]  J. Gore,et al.  Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T , 2016, Multiple sclerosis.

[58]  C. Pfueller,et al.  Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis , 2012, Neurology.

[59]  Nikos Evangelou,et al.  The Central Vein Sign in Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[60]  Yulin Ge,et al.  Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. , 2008, Archives of neurology.

[61]  S. Nelson,et al.  Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron , 2008, Annals of neurology.

[62]  Bertrand K. Hassani.  The Consensus Approach , 2016 .

[63]  Robert J Fox,et al.  Observations on the brain vasculature in multiple sclerosis: A historical perspective. , 2014, Multiple sclerosis and related disorders.

[64]  Dmitriy A Yablonskiy,et al.  Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesions , 2014, Multiple sclerosis.

[65]  O. Ciccarelli,et al.  MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES , 2016, The Lancet Neurology.

[66]  D. Bates.  Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials , 2011, Neurology.

[67]  D. Reich,et al.  “Central vessel sign” on 3T FLAIR* MRI for the differentiation of multiple sclerosis from migraine , 2015, Annals of clinical and translational neurology.